{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:01:24Z","timestamp":1783062084560,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Clin Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1472-6904-11-23","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T19:32:41Z","timestamp":1325273561000},"source":"Crossref","is-referenced-by-count":22,"title":["The association between drospirenone and hyperkalemia: a comparative-safety study"],"prefix":"10.1186","volume":"11","author":[{"given":"Steven T","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore R","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph AC","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,30]]},"reference":[{"key":"118_CR1","unstructured":"Yasmin [package insert], Wayne NJ: 2010, Bayer Healthcare Pharmaceuticals, Inc."},{"key":"118_CR2","volume-title":"Technical Report Series 877","author":"The World Health Organization","year":"1998","unstructured":"The World Health Organization: Cardiovascular disease and steroid hormone contraception. Technical Report Series 877. 1998, Geneva: The Organization"},{"key":"118_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","volume":"761","author":"P Muhn","year":"1995","unstructured":"Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E: Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995, 761: 311-335. 10.1111\/j.1749-6632.1995.tb31386.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"13","key":"118_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2165\/00002018-200427130-00003","volume":"27","author":"LA Heinemann","year":"2004","unstructured":"Heinemann LA, Dinger J: Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004, 27 (13): 1001-1018. 10.2165\/00002018-200427130-00003.","journal-title":"Drug Saf"},{"key":"118_CR5","unstructured":"Disorders of the adrenal cortex. Harrison's principles of internal medicine. Edited by: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. 2011, New York: McGraw-Hill, 18"},{"issue":"13","key":"118_CR6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","volume":"112","author":"WB White","year":"2005","unstructured":"White WB, Pitt B, Preston RA, Hanes V: Antihypertensive effects of drospirenone with 17\u03b2-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005, 112 (13): 1979-1984. 10.1161\/CIRCULATIONAHA.104.501502.","journal-title":"Circulation"},{"issue":"2","key":"118_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","volume":"48","author":"WB White","year":"2006","unstructured":"White WB, Hanes V, Chauhan V, Pitt B: Effects of a new hormone therapy, drospirenone and 17-\u03b2-estradiol, in postmenopausal women with hypertension. Hypertension. 2006, 48 (2): 246-253. 10.1161\/01.HYP.0000232179.60442.84.","journal-title":"Hypertension"},{"issue":"6","key":"118_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.amjhyper.2004.12.003","volume":"18","author":"RA Preston","year":"2005","unstructured":"Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V: Effects of drospirenone\/17-\u03b2 estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005, 18 (6): 797-804. 10.1016\/j.amjhyper.2004.12.003.","journal-title":"Am J Hypertens"},{"issue":"2","key":"118_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","volume":"61","author":"KS Parsey","year":"2000","unstructured":"Parsey KS, Pong A: An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000, 61 (2): 105-111. 10.1016\/S0010-7824(00)00083-4.","journal-title":"Contraception"},{"issue":"6","key":"118_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/15246090152543148","volume":"10","author":"EQ Freeman","year":"2001","unstructured":"Freeman EQ, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001, 10 (6): 561-569. 10.1089\/15246090152543148.","journal-title":"J Womens Health Gend Based Med"},{"issue":"1","key":"118_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0015-0282(01)01834-9","volume":"76","author":"F L\u00fcdicke","year":"2001","unstructured":"L\u00fcdicke F, Johannisson E, Helmerhorst FM, Campana A, Foidart J, Heithecker R: Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 \u03bcg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001, 76 (1): 102-107. 10.1016\/S0015-0282(01)01834-9.","journal-title":"Fertil Steril"},{"issue":"4","key":"118_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.contraception.2003.11.003","volume":"69","author":"U Gaspard","year":"2004","unstructured":"Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R: A randomized study on the influence of oral contraceptives containing ethinylestradiol combine with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004, 69 (4): 271-278. 10.1016\/j.contraception.2003.11.003.","journal-title":"Contraception"},{"issue":"5","key":"118_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.contraception.2008.06.012","volume":"78","author":"J Loughlin","year":"2008","unstructured":"Loughlin J, Seeger JD, Eng PM, Foegh M, Clifford CR, Cutone J, Walker AM: Risk of hyperkalemia in women taking ethinylestradiol\/drospirenone and other oral contraceptives. Contraception. 2008, 78 (5): 377-383. 10.1016\/j.contraception.2008.06.012.","journal-title":"Contraception"},{"key":"118_CR14","unstructured":"IMS Health: LifeLink health plan claims database: overview and study design issues. [ http:\/\/uams.edu\/cctr\/hsrcore\/Lifelink_Health_Plan_Claims_Data_DesignIssues_wcost_April2010%5B1%5D.pdf ]"},{"issue":"5","key":"118_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","volume":"75","author":"JC Dinger","year":"2007","unstructured":"Dinger JC, Heinemann LAJ, K\u00fchl-Habich D: The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007, 75 (5): 344-354. 10.1016\/j.contraception.2006.12.019.","journal-title":"Contraception"},{"issue":"8990","key":"118_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995, 346 (8990): 1582-1588.","journal-title":"Lancet"},{"issue":"8990","key":"118_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","volume":"346","author":"H Jick","year":"1995","unstructured":"Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995, 346 (8990): 1589-1593. 10.1016\/S0140-6736(95)91928-7.","journal-title":"Lancet"},{"issue":"8990","key":"118_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","volume":"346","author":"KW Bloemankamp","year":"1995","unstructured":"Bloemankamp KW, Rosendaal FR, Helmerhorst FM, B\u00fcller HR, Vandenbroucke JP: Enhancement by factor V leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995, 346 (8990): 1593-1596. 10.1016\/S0140-6736(95)91929-5.","journal-title":"Lancet"},{"issue":"7270","key":"118_CR19","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bmj.321.7270.1190","volume":"321","author":"H Jick","year":"2000","unstructured":"Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS: Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000, 321 (7270): 1190-1195. 10.1136\/bmj.321.7270.1190.","journal-title":"BMJ"},{"issue":"6","key":"118_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.contraception.2006.02.002","volume":"73","author":"SS Jick","year":"2006","unstructured":"Jick SS, Kaye JA, Russmann S, Jick H: Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006, 73 (6): 566-570. 10.1016\/j.contraception.2006.02.002.","journal-title":"Contraception"},{"issue":"7305","key":"118_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","volume":"323","author":"JM Kemmeren","year":"2001","unstructured":"Kemmeren JM, Algra A, Grobbee DE: Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001, 323 (7305): 131-134. 10.1136\/bmj.323.7305.131.","journal-title":"BMJ"},{"issue":"23","key":"118_CR22","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/jnci\/djq419","volume":"102","author":"S Gillessen","year":"2010","unstructured":"Gillessen S, Templeton A, Marra G, Kuo YF, Valtrta E, Shahinian VB: Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010, 102 (23): 1760-1770. 10.1093\/jnci\/djq419.","journal-title":"J Natl Cancer Inst"},{"key":"118_CR23","unstructured":"Noize P, Bagheri H, Durrieu G, Haramburo F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL: Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol and Drug Saf."},{"issue":"7","key":"118_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1345\/aph.1K673","volume":"42","author":"CI Jarvis","year":"2008","unstructured":"Jarvis CI, Lynch AM, Morin AK: Management strategies for premenstrual syndrome\/premenstrual dysphoric disorder. Ann Pharmacother. 2008, 42 (7): 967-978. 10.1345\/aph.1K673.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"118_CR25","first-page":"585","volume":"3","author":"D De Berardis","year":"2007","unstructured":"De Berardis D, Serroni N, Salerno RM, Ferro FM: Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag. 2007, 3 (4): 585-590.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"118_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/15246090152543148","volume":"10","author":"EW Freeman","year":"2001","unstructured":"Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001, 10 (6): 561-569. 10.1089\/15246090152543148.","journal-title":"J Womens Health Gend Based Med"},{"issue":"10","key":"118_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/00016349509021201","volume":"74","author":"M Wang","year":"1995","unstructured":"Wang M, Hammarback S, Lindhe BA, B\u00e4ckstr\u00f6m T: Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995, 74 (10): 803-808. 10.3109\/00016349509021201.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"118_CR28","unstructured":"Saha L, Kaur S, Saha PK: Pharmacotherapy of polycystic ovary syndrome-an update. Fundam Clin Pharmacol."},{"issue":"4","key":"118_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.contraception.2007.06.002","volume":"76","author":"M McAdams","year":"2007","unstructured":"McAdams M, Staffa JA, Dal Pan GJ: The concomitant prescribing of ethinyl estradiol\/drospirenone and potentially interacting drugs. Contraception. 2007, 76 (4): 278-281. 10.1016\/j.contraception.2007.06.002.","journal-title":"Contraception"},{"issue":"6","key":"118_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1872-034X.2007.00072.x","volume":"37","author":"G Tarantino","year":"2007","unstructured":"Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E: A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007, 37 (6): 410-415. 10.1111\/j.1872-034X.2007.00072.x.","journal-title":"Hepatol Res"}],"container-title":["BMC Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-11-23.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6904-11-23\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-11-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T05:52:29Z","timestamp":1468648349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1186\/1472-6904-11-23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["118"],"URL":"https:\/\/doi.org\/10.1186\/1472-6904-11-23","relation":{},"ISSN":["1472-6904"],"issn-type":[{"value":"1472-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"article-number":"23"}}